Design: Safety and immunogenicity of a recombinant 14kDa,fattyacid-binding protein(FABP) from Schistosoma mansoni (rSm14) were evaluated through an open,non-placebo-controlled,dose-standardized trial, performed at a single research site.The vaccine was formulated with glucopyranosyl lipid A(GLA) adjuvant inanoil-in-water emulsion(SE) and investigated in 20 male volunteers from a non-endemic
area for schistosomiasis in the state of Rio de Janeiro,Brazil. Fifty microgram rSm14 with 10 g GLA-SE (rSm14/GLA-SE)/dose were given intramuscularly three times with 30-day intervals.Participants were assessed clinically, biochemically and immunologically for up to 120 days.